Talecris Biotherapeutics
4101 Research Commons
79 T.W. Alexander Drive
Research Triangle Park
North Carolina
27709
United States
Tel: 919-316-6316
Fax: 919-316-6673
Website: http://www.talecris.com/
About Talecris Biotherapeutics
Talecris Biotherapeutics: A new approach to a proud history of patient careTalecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products.
Talecris is well-positioned to pursue their bold vision...
• Through our people. Talecris is a newer company, but our employees include the same people who provided plasma protein products and services from Bayer Biological Products. This continuity of leadership, depth of knowledge and experience, understanding of market and patient needs, and commitment to customer service is our most important resource.
• Through our technology and state-of-the-art facilities. Talecris boasts a state-of-the-art fractionation and production facility located in Clayton, North Carolina. Premium therapies are produced with extensive use of patented process technologies. Our fractionation capacity is significantly increased by the addition of the recognized plasma fractionation expertise of Precision Pharma Services and its employees based in Melville, New York. Precision Pharma had a long-standing relationship with Bayer, providing fractionation services to produce intermediate materials for our key products, Gamunex® and Prolastin®. Precision’s resources will increase our business flexibility by providing complementary manufacturing capabilities and a growing contract services business. As a result, Talecris is well-positioned to meet future demands for our key products.
• Through a more focused entrepreneurial approach. Building on the long history of innovation, Talecris Biotherapeutics will bring a more focused, entrepreneurial approach to new product development, application of cutting-edge manufacturing technologies, and marketing and customer services. The company established the division of Talecris Plasma Resources and embarked on a quest to build the industry's premier plasma collection business to meet the growing demands for our products.
• Through our leadership. Our senior management team includes experienced industry professionals as well as seasoned business and financial experts. The result is a leadership team that knows how to effectively apply resources toward new products, technologies, and services that provide value to our customers and business partners and optimum benefit for our patients.
Talecris is the people you know and trust bringing you a whole new world of possibilities. We look forward to your continuing support as we combine our vast experience and commitment to patient care, apply our bold vision, and thus become a recognized global leader in biotherapeutics.
131 articles about Talecris Biotherapeutics
-
Grifols' CEO Sees Few Cuts at Talecris Biotherapeutics; Expects Layoffs to be Less Than 5%
6/8/2011
-
Grifols Announces the Completion of its Acquisition of Talecris Biotherapeutics and the Listing of its ADSs on NASDAQ
6/6/2011
-
Grifols and Talecris Biotherapeutics Announce the FTC Has Accepted the Consent Agreement for Public Comment
6/1/2011
-
Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting
5/3/2011
-
Grifols to Sell Assets to Clear Way for Talecris Biotherapeutics Takeover
5/2/2011
-
Talecris Biotherapeutics Announces First Quarter 2011 Results
4/28/2011
-
Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
4/14/2011
-
Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
3/7/2011
-
Talecris Biotherapeutics Receives EU Orphan Drug Designation for Plasmin (Human) as a Treatment for Acute Peripheral Arterial Occlusion
3/4/2011
-
Grifols and Talecris Biotherapeutics Announce the Outside Date of Their Merger Agreement has been Extended to June 30, 2011
3/4/2011
-
Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
2/24/2011
-
Talecris Biotherapeutics Shareholders Vote for $3B Grifols Sale
2/15/2011
-
Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
2/9/2011
-
Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
2/9/2011
-
Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
1/14/2011
-
Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics
1/6/2011
-
Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
12/14/2010
-
Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN(R)-C
12/10/2010
-
Grifols Signs Term Loan Agreements Related To Talecris Biotherapeutics Acquisition for USD 3.4 Billion
11/24/2010
-
Talecris Biotherapeutics: Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
11/15/2010